114 related articles for article (PubMed ID: 28499648)
1. Ovarian cancer spheroid shrinkage following continuous exposure to cisplatin is a function of spheroid diameter.
Tanenbaum LM; Mantzavinou A; Subramanyam KS; Del Carmen MG; Cima MJ
Gynecol Oncol; 2017 Jul; 146(1):161-169. PubMed ID: 28499648
[TBL] [Abstract][Full Text] [Related]
2. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models.
Ye H; Tanenbaum LM; Na YJ; Mantzavinou A; Fulci G; Del Carmen MG; Birrer MJ; Cima MJ
J Control Release; 2015 Dec; 220(Pt A):358-367. PubMed ID: 26548976
[TBL] [Abstract][Full Text] [Related]
3. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
4. Laminin-1-derived scrambled peptide AG73T disaggregates laminin-1-induced ovarian cancer cell spheroids and improves the efficacy of cisplatin.
Yoshida Y; Kurokawa T; Nishikawa Y; Orisa M; Kleinman HK; Kotsuji F
Int J Oncol; 2008 Mar; 32(3):673-81. PubMed ID: 18292945
[TBL] [Abstract][Full Text] [Related]
5. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
[TBL] [Abstract][Full Text] [Related]
6. Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer?
Petignat P; du Bois A; Bruchim I; Fink D; Provencher DM
Crit Rev Oncol Hematol; 2007 May; 62(2):137-47. PubMed ID: 17188887
[TBL] [Abstract][Full Text] [Related]
7. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
[TBL] [Abstract][Full Text] [Related]
8. Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays.
Raghavan S; Ward MR; Rowley KR; Wold RM; Takayama S; Buckanovich RJ; Mehta G
Gynecol Oncol; 2015 Jul; 138(1):181-9. PubMed ID: 25913133
[TBL] [Abstract][Full Text] [Related]
9. The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration.
Gunay G; Kirit HA; Kamatar A; Baghdasaryan O; Hamsici S; Acar H
Gynecol Oncol; 2020 Nov; 159(2):563-572. PubMed ID: 32958270
[TBL] [Abstract][Full Text] [Related]
10. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.
Li SD; Howell SB
Mol Pharm; 2010 Feb; 7(1):280-90. PubMed ID: 19994852
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
13. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
Feun LG; Blessing JA; Major FJ; DiSaia PJ; Alvarez RD; Berek JS
Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
[TBL] [Abstract][Full Text] [Related]
15. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
16. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
17. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
18. A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer.
Sarkar S; Malekshah OM; Nomani A; Patel N; Hatefi A
Cancer Med; 2018 Aug; 7(8):3630-3641. PubMed ID: 29926538
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal chemotherapy for advanced epithelial ovarian malignancy: lessons learned.
Bunting M; Chan W; Brand A; Blomfield P
Aust N Z J Obstet Gynaecol; 2009 Dec; 49(6):667-71. PubMed ID: 20070720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]